Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Scientists struggle to understand neurodegeneration in the SNAP syndrome.
Postmortem pathology confirms that some people who were diagnosed with AD during life had no appreciable amyloid in the brain, leaving researchers to puzzle over what caused their cognitive decline.
Paper Alert: Longitudinal Data Support CSF Neurogranin as an Early Synaptic Marker of Alzheimer’s Disease
Neurogranin could be a promising early CSF biomarker of Alzheimer’s disease.
Moving toward a common standard for fluid-based Alzheimer’s diagnosis in routine clinical care, an intergovernmental metrology agency has certified a way of quantifying Aβ42.
Meet RBM45. This RNA-binding protein and relatively new player in the ALS field associates with stress-induced structures in the cytoplasm and nucleus.
NIH announced a five-year study of Alzheimer’s biomarkers in middle-aged people with Down’s syndrome.
Researchers will follow former football players at risk for the disorder to identify the best biomarkers and clinical criteria.
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
Seeking strength in numbers, families gathered to swap stories and to learn about an upcoming DIAN-TU therapy trial geared specifically to their particular form of early onset AD.
A PET study comparing amyloid, tau, and volumetric imaging in preclinical AD identifies a region where local tangles correlate with brain-wide amyloid.
At AAIC, 28 scientific presentations and five attendant meetings of the Dominantly Inherited Alzheimer’s Network showed how data is rolling in while the platform expands to more countries and a second therapeutic trial.
Serial measurements on hundreds of people in the Dominantly Inherited Alzheimer’s Network put proposed staging diagrams on an empirical footing. CSF markers sTREM2 and VILIP-1 track tau.